{"id":"0-33-ropivacaine-250ml","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Other local anesthetics","interaction":"Increased risk of systemic toxicity"},{"drug":"Sedatives","interaction":"Enhanced sedative effects"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"10%","severity":"Mild"},{"effect":"Dizziness","drugRate":"8%","severity":"Mild"},{"effect":"Headache","drugRate":"5%","severity":"Mild"},{"effect":"Vomiting","drugRate":"4%","severity":"Mild"},{"effect":"Back pain","drugRate":"3%","severity":"Mild"}],"contraindications":["Hypersensitivity to ropivacaine or other amide-type local anesthetics","Severe shock","Infection at the injection site"],"specialPopulations":{"Lactation":"Caution advised; excretion into breast milk is possible","Pregnancy":"Category B - No evidence of harm in animal studies, but no adequate human studies","Renal Impairment":"May require dose adjustment due to reduced clearance","Hepatic Impairment":"May require dose adjustment due to reduced metabolism"}},"trials":[],"_chembl":{"chemblId":"CHEMBL1077896","moleculeType":"Small molecule","molecularWeight":"274.41"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2023-01-01","type":"Launch","milestone":"Initial market release in China","regulator":"NMPA"}],"_dailymed":null,"aiSummary":"Ropivacaine is a local anesthetic used primarily for regional anesthesia and pain management. It is less cardiotoxic than bupivacaine and has a longer duration of action compared to lidocaine. The 0.33% formulation in a 250ml solution is typically used for peripheral nerve blocks and epidural anesthesia. Due to its lower toxicity profile, it is often preferred in patients at higher risk of systemic toxicity. However, the product from Guangzhou General Hospital of Guangzhou Military Command does not have an FDA label, which may limit its use in certain markets.","ecosystem":[],"mechanism":{"target":"Voltage-gated sodium channels","novelty":"Ropivacaine has a lower potential for cardiotoxicity compared to other amide-type local anesthetics like bupivacaine.","modality":"Injection","drugClass":"Local anesthetic","explanation":"Ropivacaine works by reversibly binding to and blocking voltage-gated sodium channels in nerve cells, which prevents the generation and conduction of action potentials.","oneSentence":"Ropivacaine is a local anesthetic that blocks sodium channels, preventing the propagation of nerve impulses.","technicalDetail":"The drug specifically targets the inactivated state of sodium channels, leading to a more prolonged block compared to other local anesthetics."},"_scrapedAt":"2026-03-28T00:23:49.954Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"N/A","launchDate":"N/A","annualCostUS":"N/A","currentRevenue":"N/A","patientPopulation":"N/A","peakSalesEstimate":"N/A"},"references":[],"biosimilars":[],"competitors":[{"name":"Bupivacaine","company":"Various manufacturers"},{"name":"Lidocaine","company":"Various manufacturers"}],"indications":{"approved":["Peripheral nerve blocks","Epidural anesthesia"],"offLabel":["Postoperative pain management"],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01872494","phase":"PHASE4","title":"The Impact of Local Analgesia for Postoperative Analgesia in Posterior Thoracolumbar Operation","status":"COMPLETED","sponsor":"Guangzhou General Hospital of Guangzhou Military Command","startDate":"2013-05","conditions":"Pain","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"0.33% ropivacaine 250ml","genericName":"0.33% ropivacaine 250ml","companyName":"Guangzhou General Hospital of Guangzhou Military Command","companyId":"guangzhou-general-hospital-of-guangzhou-military-command","modality":"Small molecule","firstApprovalDate":"N/A","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}